Dr. Reddys Laboratories Ltd.
BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1243.00
8.40 (0.68%) Dr Reddy's Laboratories informs about press release
Date: 16-12-2022Dr Reddy's Laboratories has informed that Aurigene Oncology, a wholly owned subsidiary of Dr Reddy's Laboratories, reports results of AUR101 in Phase II Study in Patients with moderate to severe psoriasis. A press release in this regard is enclosed.
The above information is a part of company’s filings submitted to BSE.